The Novo, Pfizer and Nan Fung-backed oncology therapy developer priced an upsized offering above its range and is now valued above $1bn.
Bolt Biotherapeutics, a US-based cancer drug developer that counts pharmaceutical firms Pfizer and Novo and real estate developer Nan Fung as investors, went public on Friday raising $230m. The company issued 11.5 million shares priced at $20 each in the initial public offering, increased from 8.8 million, while the share price was above the IPO’s…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.